Study summary

Belzutifan beat everolimus after earlier treatments

LITESPARK-005 trial · Phase 3, randomized · Published August 2024, New England Journal of Medicine

What was tested

Belzutifan against everolimus for advanced clear cell kidney cancer after immunotherapy and a VEGF drug.

What they found

Belzutifan delayed growth and shrank tumors more often than everolimus.
Overall survival did not significantly differ.

What it means

Established belzutifan as a later-line option; now moving earlier.

N Engl J Med, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.